Jens Bjørheim-arkiv - BioStock

Jens Bjørheim, CMO Ultimovacs

Ultimovacs CMO explains phase II mesothelioma data

14 June, 2023

Ultimovacs progresses to last cohort in TENDU study

Ultimovacs progresses to last cohort in TENDU study

8 February, 2022

Ultimovacs sees first patient enrolled in DOVACC trial

Ultimovacs sees first patient enrolled in DOVACC trial

17 December, 2021

positive data

Positive phase I data for Ultimovacs

14 October, 2021

Ultimovacs enters next step in new vaccine platform development

6 October, 2021

New data gives weight to Ultimovacs’s cancer vaccine

20 May, 2021

Ultimovacs Begins Clinical Evaluation of Novel TET-Platform

26 February, 2021